tbuckley/cabot-search huggingface dataset:
Model of integrated mental health video consultations for people with depression or anxiety in primary care (PROVIDE-C): assessor masked, multicentre, randomised controlled trial
Authors: Markus W Haun, Justus Tönnies, Mechthild Hartmann, Alina Wildenauer, Michel Wensing, Joachim Szecsenyi, Manuel Feißt, Moritz Pohl, Markus Vomhof, Andrea Icks, Hans-Christoph Friederich
Journal: BMJ (2024)

Abstract Objective To evaluate whether an integrated mental health video consultation approach (PROVIDE model) can improve symptoms compared with usual care in adults with depression and anxiety disorders attending primary care. Design Assessor masked, multicentre, randomised controlled trial (PROVIDE-C). Setting In 29 primary care practices in Germany, working remotely online from one trial hub. Participants 376 adults (18-81 years) who presented to their general practitioner (GP) with depression or anxiety, or both. Intervention Participants were randomised (1:1) to receive the PROVIDE model (n=187) or usual care (n=189). Usual care was provided by GPs through interventions such as brief counselling and psychotropic medication prescriptions and may or may not have included referrals to mental health specialists. The PROVIDE model comprised transdiagnostic treatment provided through five real-time video sessions between the patient at the primary care practice and a mental health specialist at an offsite location. Main outcome measures The primary outcome was the absolute change in the mean severity of depressive and anxiety symptoms measured using the patient health questionnaire anxiety and depression scale (PHQ-ADS) at six months, in the intention-to-treat population. Secondary outcomes, measured at six and 12 months, included PHQ-ADS subscores, psychological distress related to somatic symptoms, recovery, health related quality of life, quality and patient centredness of chronic illness care, and adverse events. Results Between 24 March 2020 and 23 November 2021, 376 patients were randomised into treatment groups. Mean age was 45 years (standard deviation (SD) 14), 63% of the participants were female, and mean PHQ-ADS-score was 26 points (SD 7.6). Compared with usual care, the PROVIDE intervention led to improvements in severity of depressive and anxiety symptom (adjusted mean change difference in the PHQ-ADS score −2.4 points (95% confidence interval −4.5 to −0.4), P=0.02) at six months. The effects were sustained at 12 months (−2.9 (−5.0 to −0.7), P&lt;0.01). No serious adverse events were reported in either group. Conclusions Through relatively low intensity treatment, the PROVIDE model led to a decrease in depressive and anxiety symptoms with small effects in the short and long term. Depression and anxiety disorders are prevalent and therefore the small effect might cumulatively impact on population health in this population. Trial registration ClinicalTrials.gov NCT04316572 .
New-Onset Vulvar Edema in a Pediatric Patient
Authors: Eugeni Prat Colilles, Adrià Plana Pla, Isabel Bielsa Marsol
Journal: JAMA Dermatology (2024)

A female pediatric patient presents with asymptomatic vulvar edema and swelling, erythema, and palpable induration on the labia minora and majora of the vulva. What is your diagnosis?
Dermatology Encounters After Solid Organ Transplant
Authors: Surya A. Veerabagu, Kai-Ping Liao, Anokhi Jambusaria-Pahlajani, Lee Wheless, Mackenzie R. Wehner
Journal: JAMA Dermatology (2024)

This cohort study describes the use of the Skin and UV Neoplasia Transplant Risk Assessment Calculator tool for transplant recipients.
Life Cycle Analysis of a Pediatric Surgical Kit—A Target to Reduce Operating Room Waste
Authors: Alison Lehane, Gwyneth A. Sullivan, Jennifer Dunn, Mallory Perez, Charesa J. Smith, Mehul V. Raval
Journal: JAMA Surgery (2024)

This study uses life cycle analysis to comprehensively evaluate the environmental impact of a pediatric surgical kit, including water consumption and greenhouse gas emissions.
Antibiotic Prophylaxis for Surgical Site Infection After Traumatic Hollow Viscus Injury
Authors: Janelle Cyprich, Amy H. Kaji, Alexandra Moulton, Hye Kwang E. Kim, Alexander C. Schwed, Jessica A. Keeley
Journal: JAMA Surgery (2024)

This cohort study investigates the association between antibiotic prophylaxis and surgical site infection after traumatic hollow viscus injury.
Application of Risk-Based Cancer Screening in Patients With Dermatomyositis
Authors: Caroline J. Stone, Daniella Forman Faden, Lillian Xie, Lais Lopes Almeida Gomes, Emily Z. Hejazi, Victoria P. Werth, Katharina S. Shaw
Journal: JAMA Dermatology (2024)

This cohort study investigates the performance of the International Myositis Assessment and Clinical Studies Group cancer screening recommendations in a community setting.
Semaglutide and Opioid Overdose Risk in Patients With Type 2 Diabetes and Opioid Use Disorder
Authors: William Wang, Nora D. Volkow, QuangQiu Wang, Nathan A. Berger, Pamela B. Davis, David C. Kaelber, Rong Xu
Journal: JAMA Network Open (2024)

This cohort study uses emulation target trial methods to evaluate whether semaglutide is associated with lower rates of opioid overdose among patients with type 2 diabetes (T2D) and opioid use disorder (OUD).
Mitochondria as a primary determinant of angiogenic modality in pulmonary arterial hypertension
Authors: Maki Niihori, Joel James, Mathews V. Varghese, Nolan McClain, Odunayo Susan Lawal, Rohit C. Philip, Brenda K. Baggett, Dmitry A. Goncharov, Vinicio de Jesus Perez, Elena A. Goncharova, Ruslan Rafikov, Olga Rafikova
Journal: The Journal of Experimental Medicine (2024)

Impaired pulmonary angiogenesis plays a pivotal role in the progression of pulmonary arterial hypertension (PAH) and patient mortality, yet the molecular mechanisms driving this process remain enigmatic. Our study uncovered a striking connection between mitochondrial dysfunction (MD), caused by a humanized mutation in the NFU1 gene, and severely disrupted pulmonary angiogenesis in adult lungs. Restoring the bioavailability of the NFU1 downstream target, lipoic acid (LA), alleviated MD and angiogenic deficiency and rescued the progressive PAH phenotype in the NFU1G206C model. Notably, significant NFU1 expression and signaling insufficiencies were also identified in idiopathic PAH (iPAH) patients’ lungs, emphasizing this study’s relevance beyond NFU1 mutation cases. The remarkable improvement in mitochondrial function of PAH patient-derived pulmonary artery endothelial cells (PAECs) following LA supplementation introduces LA as a potential therapeutic approach. In conclusion, this study unveils a novel role for MD in dysregulated pulmonary angiogenesis and PAH manifestation, emphasizing the need to correct MD in PAH patients with unrecognized NFU1/LA deficiency.
Humoral immunity after mRNA SARS-CoV-2 omicron JN.1 vaccination
Authors: Christine Happle, Markus Hoffmann, Amy Kempf, Inga Nehlmeier, Metodi V Stankov, Noemi Calderon Hampel, Torsten Witte, Stefan Pöhlmann, Georg M N Behrens, Alexandra Dopfer-Jablonka
Journal: The Lancet Infectious Diseases (2024)
Highly sensitive detection platform-based diagnosis of oesophageal squamous cell carcinoma in China: a multicentre, case–control, diagnostic study
Authors: Yu Wang, Shan Xing, Yi-Wei Xu, Qing-Xia Xu, Ming-Fang Ji, Yu-Hui Peng, Ya-Xian Wu, Meng Wu, Ning Xue, Biao Zhang, Shang-Hang Xie, Rui-Dan Zhu, Xin-Yuan Ou, Qi Huang, Bo-Yu Tian, Hui-Lan Li, Yu Jiang, Xiao-Bin Yao, Jian-Pei Li, Li Ling, Su-Mei Cao, Qian Zhong, Wan-Li Liu, Mu-Sheng Zeng
Journal: The Lancet Digital Health (2024)
Deep learning assessment of senescence-associated nuclear morphologies in mammary tissue from healthy female donors to predict future risk of breast cancer: a retrospective cohort study
Authors: Indra Heckenbach, Mark Powell, Sophia Fuller, Jill Henry, Sam Rysdyk, Jenny Cui, Amanuel Abraha Teklu, Eric Verdin, Christopher Benz, Morten Scheibye-Knudsen
Journal: The Lancet Digital Health (2024)
Symptom trajectories in infancy for the prediction of subsequent wheeze and asthma in the BILD and PASTURE cohorts: a dynamic network analysis
Authors: Uri Nahum, Olga Gorlanova, Fabienne Decrue, Heide Oller, Edgar Delgado-Eckert, Andreas Böck, Sven Schulzke, Philipp Latzin, Bianca Schaub, Anne M Karvonen, Roger Lauener, Amandine Divaret-Chauveau, Sabina Illi, Caroline Roduit, Erika von Mutius, Urs Frey
Journal: The Lancet Digital Health (2024)
Impact of the COVID-19 pandemic on health-care use among patients with cancer in England, UK: a comprehensive phase-by-phase time-series analysis across attendance types for 38 cancers
Authors: Yen Yi Tan, Wai Hoong Chang, Michail Katsoulis, Spiros Denaxas, Kayla C King, Murray P Cox, Charles Davie, Francois Balloux, Alvina G Lai
Journal: The Lancet Digital Health (2024)
Endoscopic ultrasound-guided gallbladder drainage using a forward-viewing echoendoscope for Roux-en-Y reconstruction
Authors: Ono Michihiro, Oiwa Shutaro, Yokoyama Ryota, Saito Seiya, Uesugi Atsushi, Abe Tomoyuki, Maeda Masahiro
Journal: Endoscopy (2024)
Complete closure after colorectal endoscopic submucosal dissection with a re-openable clip with a sharp claw
Authors: Naohisa Yoshida, Ryohei Hirose, Osamu Dohi, Yoshikazu Inagaki, Takaaki Murakami, Yutaka Inada, Yasutaka Morimoto, Reo Kobayashi, Ken Inoue, Elsayed Ghoneem, Yoshito Itoh
Journal: Endoscopy (2024)

Background and Aims: The MANTIS Closure Device (MCD: Boston Scientific, USA), a reopenable clip with a sharp claw, is a closure device used after endoscopic submucosal dissection (ESD). We aimed to evaluate the effectiveness of MCD for fast and complete closure after colorectal ESD. Methods: Cases that underwent closure with MCD after ESD of colorectal lesions 20-60 mm between April 2023 and January 2024 were reviewed. The primary endpoint was the complete closure of the ESD defect with MCD. Secondary endpoints included closure time, delayed bleeding (DB), perforation (DP), and post-ESD coagulation syndrome (PECS). The usage of MCD involved 1. grasping the anal-side mucosa around the defect, 2. pushing it toward the oral-side mucosa around the defect and deploying it, 3. adding several re-openable clips (Sure clip, Micro-Tech, China) for complete closure. Results: Sixty-one cases with MCD were analyzed. The mean tumor size was 32.3±9.2 mm. The complete closure rate was 98.4% and closure time (mean±standard deviation: SD) was 6.9±2.6 mins. The number of MCD and Sure clip (mean±SD) were 1.0±0.1 and 4.7±1.4. The rates of DP/DB/PECS were 0%, 0%, and 9.8%, respectively. Conclusion: Fast and complete closure after colorectal ESD was successfully achieved using MCD.
Diversity, equity, and inclusion in gastrointestinal endoscopy: European Society of Gastrointestinal Endoscopy Position Statement
Authors: Maria Pellisé, Alanna Ebigbo, Yasmijn J. van Herwaarden, Hannah van Malenstein, Ioannis S. Papanikolaou, Katarzyna M. Pawlak, Andrei M. Voiosu, Shimaa Afify, Asma Alkandari, Isis K. Araujo, Bidour Awadelkarim, Fabiana Benjaminov, Maria García Campos, Sridhar Sundaram, Konstantinos Triantafyllou, Andreea Vlad, Marianna Arvanitakis, Raf Bisschops, Cesare Hassan, Helmut Messmann, Ian M. Gralnek
Journal: Endoscopy (2024)

Statements 1 The European Society of Gastrointestinal Endoscopy (ESGE) adheres to the overarching principles of equality of opportunity, fair treatment, nondiscrimination, and diversity of health care professionals. 2 ESGE strongly supports the creation of collaborations within and between national and international endoscopy societies to disseminate the principles of diversity, equality, and inclusion (DEI) in the field of gastrointestinal (GI) endoscopy. 3 ESGE aims to reflect the diversity of its membership in all its scientific and educational activities. 4 ESGE supports the fostering of collaborative work settings that empower all members of the endoscopy team to reach their full potential. 5 ESGE supports international and national endoscopy societies in promoting equitable access to high quality endoscopy training. 6 ESGE recommends the implementation of ergonomic principles in endoscopy units to prevent injuries and to provide adapted workplace conditions for personnel with disabilities and/or special needs. 7 ESGE recommends comprehensive mentorship, that includes diverse backgrounds, and equitable sponsorship for professional development, training, and academic excellence. 8 ESGE recommends that endoscopists actively identify, discuss, and attempt to accommodate reasonable patient preferences and expectations regarding endoscopy procedures. 9 ESGE advocates for educational and awareness campaigns targeting both health care professionals and patients, as well as the adoption of cost-effective health care strategies to address disparities and enhance equity in endoscopy care. 10 ESGE is committed to increasing support for underrepresented scholars and minorities pursuing research in endoscopy. 11 ESGE identifies mentorship and sponsorship as factors that may mitigate the barriers to academic careers for underrepresented endoscopy scholars. 12 ESGE recognizes the need to increase awareness of diversity, equity, and inclusion (DEI) in the field of endoscopy and supports publications on these topics.
Exploring <scp>CD26</scp><sup>−/lo</sup> subpopulations of lymphocytes in asthma phenotype and severity: A novel <scp>CD4</scp><sup>+</sup> T cell subset expressing archetypical granulocyte proteins
Authors: Sara Vázquez‐Mera, Laura Martelo‐Vidal, Pablo Miguéns‐Suárez, Susana Belén Bravo, Paula Saavedra‐Nieves, Pilar Arias, Antía Ferreiro‐Posse, Juan Vázquez‐Lago, Francisco Javier Salgado, Francisco Javier González‐Barcala, Juan José Nieto‐Fontarigo
Journal: Allergy (2024)

Abstract Background Asthma pathology may induce changes in naïve/memory lymphocyte proportions assessable through the evaluation of surface CD26 (dipeptidyl peptidase 4/DPP4) levels. Our aim was to investigate the association of asthma phenotype/severity with the relative frequency of CD26 −/lo , CD26 int and CD26 hi subsets within different lymphocyte populations. Methods The proportion of CD26 −/lo , CD26 int and CD26 hi subsets within CD4 + effector T cells (T eff ), total CD4 − lymphocytes, γδ‐T cells, NK cells and NKT cells was measured in peripheral blood samples from healthy ( N = 30) and asthma ( N = 119) donors with different phenotypes/severities by flow cytometry. We performed K‐means clustering analysis and further characterised the CD4 + CD26 −/lo T eff cell subset by LC–MS/MS and immunofluorescence. Results Cluster analysis including clinical and flow cytometry data resulted in four groups, two of them with opposite inflammatory profiles (neutrophilic vs. eosinophilic). Neutrophilic asthma presented reduced CD4 − CD26 hi cells, which negatively correlated with systemic inflammation. Eosinophilic asthma displayed a general expansion of CD26 −/lo subsets. Specifically, CD4 + CD26 −/lo T eff expansion was confirmed in asthma, especially in atopic patients. Proteomic characterisation of this subset with a T EM /T EMRA phenotype revealed upregulated levels of innate (e.g. MPO and RNASE2) and cytoskeleton/extracellular matrix (e.g. MMP9 and ACTN1) proteins. Immunofluorescence assays confirmed the presence of atypical proteins for CD4 + T cells, and an enrichment in ‘flower‐like’ nuclei and MMP9/RNASE2 levels in CD4 + CD26 −/lo T eff compared to CD4 + T lymphocytes. Conclusion There is an association between CD26 levels in different lymphocyte subsets and asthma phenotype/severity. CD4 + CD26 −/lo T EMRA cells expressing innate proteins specific to eosinophils/neutrophils could be determinant in sustaining long‐term inflammation in adult allergic asthma.
The Gastroscopy RAte of Cleanliness Evaluation (GRACE) Scale: an international reliability and validation study
Authors: Gianluca Esposito, Emanuele Dilaghi, Cristina Santos, Irene Ligato, Investigators GRACE, Bruno Annibale, Mario Dinis-Ribeiro, Miguel Areia
Journal: Endoscopy (2024)

Background and study aims: mucosal visualization during upper gastrointestinal (UGI) endoscopy can be impaired by the presence of foam, bubbles, and mucus. Some UGI endoscopy visibility scales were proposed but without a multicenter validation. This study aimed to develop and validate the Gastroscopy RAte of Cleanliness Evaluation (GRACE) scale. Patients and methods: a multicenter international cross-sectional study was conducted. The GRACE scale is based on a score from 0-worst to 3-excellent of esophagus, stomach, and duodenum, for a total ranging from 0 to 9. In the first phase, four expert endoscopists evaluated 60 selected images twice with a two-week interval; in the second phase, the same 60 images were scored twice by one expert and one non-expert endoscopist from 27 different Endoscopy Departments worldwide. For reproducibility assessment and clinical validation, a real-time scale application was performed on consecutive patients undergoing gastroscopy in each center. Results: in the internal validation, the interobserver agreement was 0.81 (95%CI[0.73-0.87]) and 0.80 (95%CI[0.72-0.86]), with a reliability of 0.73 (95%CI[0.63-0.82]) and 0.72 (95%CI[0.63-0.81]), in the two rounds, respectively. In the external validation, the overall interobserver agreement was 0.85 (95%CI[0.82-0.88]) with a reliability of 0.79 (95%CI[0.73-0.84]). In the real-time evaluation phase, the overall percentage of correct classifications was 0.80 (95%CI[0.77-0.82]). Conclusions: the GRACE scale showed good interobserver agreement and reliability and good validity. The spread of this scale could enhance the quality and standardize the cleanliness of the mucosa assessment during UGI endoscopy, pushing endoscopists to obtain excellent visibility and reducing the risk of missing lesions.
Peroxidase‐Mimetic Iron Silicate Nanosheets Coordinated with Indocyanine Green for Enhanced Anti‐Tumor Therapy
Authors: Shuairu Zhu, Hongwei Xu, Wanying Guo, Mei Yang, Huiling Tan, Shaosong Hou, Jie Yao, Han Luo, Yongchao Yao, Jingxiang Zhao, Yonggang Wei, Xuping Sun, Binwu Ying
Journal: Advanced Healthcare Materials (2024)

Abstract The versatile element composition and multifunctional properties of biodegradable silicates have attracted significant attention in cancer therapeutics. However, their application as nanozymes is often limited by suboptimal catalytic efficiency and insufficient intratumoral retention. In this study, the hydrothermal synthesis of iron silicate (FeSi) nanosheets are reported exhibiting exceptional peroxidase (POD)‐like activity (136.7 U mg −1 ), outperforming most reported iron‐based nanozymes. Density functional theory calculations revealed that the introduction of Si into the catalyst enhances H 2 O 2 adsorption and dissociation of Fe sites, leading to superior POD performance. Furthermore, the FeSi nanosheets are modified with Indocyanine Green (ICG) to facilitate targeted aggregation‐potentiated therapy. The integration of ICG improved tumor penetration and retention of the FeSi nanosheets, significantly increasing their reactive oxygen species production and bolstering therapeutic efficacy.
A Study on Overcoming Post‐TACE Drug Resistance in HCC Based on Controllable Oxygen Release‐Magnetic Hyperthermia Therapy
Authors: Jin‐Xin Huang, Wei‐Hua Zhang, Ye‐Ming Wu, Jian‐Yu Hu, Huan Long, Hai‐Dong Zhu, Jian‐Qiong Zhang, Gao‐Jun Teng, Fei Xiong
Journal: Advanced Healthcare Materials (2024)

Drug-eluting bead transcatheter arterial chemoembolization (D-TACE) is one of the first-line treatment for intermediate hepatocellular carcinoma (HCC). However, the dual hypoxia microenvironment, due to inherent tumor hypoxia and TACE-induced hypoxia, triggers drug resistance in HCC. To address this challenge, the study develops multicavitary microspheres capable of encapsulating oxygen and harnessing magnetic hyperthermia to enhance oxygen permeability. The novel multicavitary oxygen-encapsulated magnetothermal drug-eluting microspheres (OTD-Ms) effectively reduce hypoxia-related proteins (HIF-1α, VEGF-A) and drug resistance (P-gp) both in vitro and in vivo. Moreover, these microspheres demonstrate improved TACE efficacy and enhance survival rates in a rabbit VX-2 tumor model, suggesting their potential for HCC treatment.
Constructing the cGAMP‐Aluminum Nanoparticles as a Vaccine Adjuvant‐Delivery System (VADS) for Developing the Efficient Pulmonary COVID‐19 Subunit Vaccines
Authors: Ning Wang, Can Wang, Chunliu Wei, Minnan Chen, Yuhao Gao, Yuxi Zhang, Ting Wang
Journal: Advanced Healthcare Materials (2024)

Abstract The cGAMP‐aluminum nanoparticles (CAN) are engineered as a vaccine adjuvant‐delivery system to carry mixed RBD (receptor‐binding domain) of the original severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) and its new variant for developing bivalent pulmonary coronavirus disease 2019 (COVID‐19) vaccines (biRBD‐CAN). High phosphophilicity/adsorptivity made intrapulmonary CAN instantly form the pulmonary ingredient‐coated CAN (piCAN) to possess biomimetic features enhancing biocompatibility. In vitro biRBD‐CAN sparked APCs (antigen‐presenting cells) to mature and make extra reactive oxygen species, engendered lysosome escape effects and enhanced proteasome activities. Through activating the intracellular stimulator of interferon genes (STING) and nucleotide‐binding domain and leucine‐rich repeat and pyrin domain containing proteins 3 (NALP3) inflammasome pathways to exert synergy between cGAMP and AN, biRBD‐CAN stimulated APCs to secret cytokines favoring mixed Th1/Th2 immunoresponses. Mice bearing twice intrapulmonary biRBD‐CAN produced high levels of mucosal antibodies, the long‐lasting systemic antibodies, and potent cytotoxic T lymphocytes which efficiently erased cells displaying cognate epitopes. Notably, biRBD‐CAN existed in mouse lungs and different lymph nodes for at least 48 h, unveiling their sustained immunostimulatory activity as the main mechanism underlying the long‐lasting immunity and memory. Hamsters bearing twice intrapulmonary biRBD‐CAN developed high resistance to pseudoviral challenges performed using different recombinant strains including the ones with distinct SARS‐CoV‐2‐spike mutations. Thus, biRBD‐CAN as a broad‐spectrum pulmonary COVID‐19 vaccine candidate may provide a tool for controlling the emerging SARS‐CoV‐2 variants.
Nanozymes in Biomedical Applications: Innovations Originated From Metal‐Organic Frameworks
Authors: Yuewu Zhao, Junjie Cheng, Zhen Li, Jine Wang, Xiaoyuan Chen
Journal: Advanced Healthcare Materials (2024)

Abstract Nanozymes exhibit significant potential in medical theranostics, environmental protection, energy development, and biopharmaceuticals due to their exceptional catalytic performance. Compared with natural enzymes, nanozymes have the advantages of simple preparation and purification, convenient production and low cost. Therefore, it is very important to prepare nanozymes quickly and efficiently, which not only helps to expand their application scope, but also can further exert their great potential in various fields. Metal‐organic frameworks (MOF) materials serve as versatile substrates for constructing nanozymes, offering unique advantages like adjustable structure, high specific surface area, and porous channels. MOF coordination nodes constructed from metal ions or metal clusters have unique properties that can be leveraged to tailor nanozyme characteristics for different applications. This review describes and analyzes recent methods for constructing nanozymes using MOF materials, and explores their application prospects in biomedicine. By expounding the preparation techniques and biomedical applications of nanozymes, this review aims to inspire researchers to develop innovative nanozyme materials and explore new application directions.
Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis
Authors: Rahul Banerjee, Rachael Sexton, Andrew J. Cowan, Aaron S. Rosenberg, Sikander Ailawadhi, S. Vincent Rajkumar, Shaji K Kumar, Angela Dispenzieri, Sagar Lonial, Brian G.M. Durie, Paul G. Richardson, Saad Z Usmani, Antje Hoering, Robert Z Orlowski
Journal: Blood (2024)